Unigestion Holding SA cut its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 33.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 460,866 shares of the biopharmaceutical company’s stock after selling 230,132 shares during the period. Unigestion Holding SA’s holdings in Bristol-Myers Squibb were worth $28,610,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Wealth Architects LLC increased its holdings in shares of Bristol-Myers Squibb by 14.0% during the third quarter. Wealth Architects LLC now owns 6,923 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 848 shares during the period. Beech Hill Advisors Inc. increased its holdings in shares of Bristol-Myers Squibb by 0.8% during the third quarter. Beech Hill Advisors Inc. now owns 105,500 shares of the biopharmaceutical company’s stock worth $6,549,000 after purchasing an additional 850 shares during the period. Signature Financial Management Inc. increased its stake in Bristol-Myers Squibb by 1.9% in the second quarter. Signature Financial Management Inc. now owns 46,006 shares of the biopharmaceutical company’s stock valued at $2,546,000 after acquiring an additional 870 shares during the last quarter. Mcmillion Capital Management Inc. increased its stake in Bristol-Myers Squibb by 1.4% in the second quarter. Mcmillion Capital Management Inc. now owns 64,044 shares of the biopharmaceutical company’s stock valued at $3,544,000 after acquiring an additional 903 shares during the last quarter. Finally, Securian Asset Management Inc increased its stake in Bristol-Myers Squibb by 0.5% in the second quarter. Securian Asset Management Inc now owns 167,108 shares of the biopharmaceutical company’s stock valued at $9,248,000 after acquiring an additional 912 shares during the last quarter. Hedge funds and other institutional investors own 72.54% of the company’s stock.
A number of research analysts recently issued reports on the stock. ValuEngine raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, July 14th. Credit Suisse Group lifted their price objective on shares of Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. BMO Capital Markets reissued a “hold” rating on shares of Bristol-Myers Squibb in a research note on Sunday, July 22nd. Morgan Stanley decreased their price objective on shares of Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday. Finally, Jefferies Financial Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Sunday, July 15th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $62.48.
NYSE BMY opened at $53.39 on Friday. The firm has a market cap of $86.49 billion, a price-to-earnings ratio of 17.74, a P/E/G ratio of 1.48 and a beta of 1.08. Bristol-Myers Squibb Co has a fifty-two week low of $46.94 and a fifty-two week high of $70.05. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.18. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. As a group, sell-side analysts predict that Bristol-Myers Squibb Co will post 3.88 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Friday, October 5th were paid a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, October 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.00%. Bristol-Myers Squibb’s payout ratio is presently 53.16%.
COPYRIGHT VIOLATION WARNING: “Unigestion Holding SA Cuts Holdings in Bristol-Myers Squibb Co (BMY)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/11/10/unigestion-holding-sa-cuts-holdings-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Featured Story: Ex-Dividend
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.